Clinical Evaluation of ARRY-614, a Dual p38/Tie2 Inhibitor for Patients with Myelodysplastic Syndromes, Identifies Unique Disease-Related and Drug-Related Biomarkers


Abstract

ARRY-614 is a potent, dual inhibitor of p38 MAPK and Tie2 that has demonstrated encouraging clinical activity and tolerability in a Phase 1 study in patients with heavily pretreated lower-risk MDS
Poster
non-peer-reviewed

Clinical Evaluation of ARRY-614, a Dual p38/Tie2 Inhibitor for Patients with Myelodysplastic Syndromes, Identifies Unique Disease-Related and Drug-Related Biomarkers


Author Information


PDF Share